TRANCOPAL Drug Patent Profile
✉ Email this page to a colleague
When do Trancopal patents expire, and what generic alternatives are available?
Trancopal is a drug marketed by Sanofi Aventis Us and is included in one NDA.
The generic ingredient in TRANCOPAL is chlormezanone. There is one drug master file entry for this compound. Additional details are available on the chlormezanone profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TRANCOPAL?
- What are the global sales for TRANCOPAL?
- What is Average Wholesale Price for TRANCOPAL?
Summary for TRANCOPAL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 93 |
| Patent Applications: | 1,012 |
| DailyMed Link: | TRANCOPAL at DailyMed |
US Patents and Regulatory Information for TRANCOPAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sanofi Aventis Us | TRANCOPAL | chlormezanone | TABLET;ORAL | 011467-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sanofi Aventis Us | TRANCOPAL | chlormezanone | TABLET;ORAL | 011467-005 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
